Active, not recruitingPhase 1NCT03435952

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

Studying Multiple endocrine neoplasia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
M.D. Anderson Cancer Center
Principal Investigator
Sarina Piha-Paul, MD, PHD
M.D. Anderson Cancer Center
Intervention
Pembrolizumab(drug)
Enrollment
18 enrolled
Eligibility
18 years · All sexes
Timeline
2018 – 2026

Study locations (1)

Collaborators

BioMed Valley Discoveries, Inc · Merck Sharp & Dohme LLC

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03435952 on ClinicalTrials.gov

Other trials for Multiple endocrine neoplasia

Additional recruiting or active studies for the same condition.

See all trials for Multiple endocrine neoplasia →

← Back to all trials